July 6, 2016
ASBM was an exhibitor during the 52nd Annual meeting of the Drug Information Association (DIA) held June 26th-30th in Philadelphia. ASBM members and staff discussed biosimilars policy with attendees, including the need for the FDA to maintain high standards for safety and efficacy when approving biosimilars. More than 65 attendees, including clinical researchers, physicians, pharmacists, […]
July 6, 2016
On June 29th, ASBM Chairman Harry L. Gewanter, MD and ASBM Steering Committee Member Andrew Spiegel, Executive Director of the Global Colon Cancer Association, gave presentations at the 6th Latin American Forum on Biosimilars, held in Brasília, Brazil. The event was also the 7th Brazilian Forum on Biosimilars. The event was attended by more than 500 […]
July 6, 2016
On June 29th, ASBM Chairman Harry L. Gewanter, MD and ASBM Steering Committee Member Andrew Spiegel, Executive Director of the Global Colon Cancer Association, gave presentations at the 6th Latin American Forum on Biosimilars, held in Brasília, Brazil. The event was also the 7th Brazilian Forum on Biosimilars. The event was attended by more than 500 […]
June 18, 2016
Biosimilar drugs hold advantages for people like me, just as biologic medicines have for millions living with life-threatening and life-diminishing diseases. Access to appropriate medication can dramatically improve disease outcome and quality of life. As more biosimilars become available, we want to ensure they are safe and affordable. I strongly support S6311 and A8648A, which […]
June 18, 2016
Biosimilar drugs hold advantages for people like me, just as biologic medicines have for millions living with life-threatening and life-diminishing diseases. Access to appropriate medication can dramatically improve disease outcome and quality of life. As more biosimilars become available, we want to ensure they are safe and affordable. I strongly support S6311 and A8648A, which […]
June 8, 2016
June 8, 2016 By Joe Bova, M.S., R.Ph. Biologic medicines currently help millions of patients suffering from serious conditions like cancer, multiple sclerosis and rheumatoid arthritis. New medicines called biosimilars, which attempt to mimic the therapeutic properties of the original biologics, are becoming available. These will create new treatment options — and cost savings — […]
June 4, 2016
ASBM Presents to New York State Pharmacy Society On June 3rd, ASBM’s Advisory Board Chair Dr. Philip Schneider, Associate Dean at the University of Arizona’s College of Pharmacy, presented to the Pharmacy Society of the State of New York (PSSNY) at a forum held at the Albany College of Pharmacy. Dr. Schneider discussed how biologics […]
June 4, 2016
ASBM Presents to New York State Pharmacy Society On June 3rd, ASBM’s Advisory Board Chair Dr. Philip Schneider, Associate Dean at the University of Arizona’s College of Pharmacy, presented to the Pharmacy Society of the State of New York (PSSNY) at a forum held at the Albany College of Pharmacy. Dr. Schneider discussed how biologics […]
May 26, 2016
by Kenneth Fisher, MD Nephrologist, ASBM Advisory Board Member Biologic medicines are one of the most powerful tools physicians have to treat patients with serious conditions like cancer, rheumatoid arthritis, hepatitis, and multiple sclerosis. Copies of these therapies, called biosimilars, are becoming available in the U.S., and offer patients new treatment options, potentially at […]
May 20, 2016
On Wednesday, June 15th, ASBM presented a one-hour educational program entitled “Biosimilars: New Choices, New Challenges” at TriStar Centennial Medical Center in Nashville, TN. Tristar Centennial educates pharmacy students from Belmont University, Lipscomb University, Murray State University, and the University of Tennessee, and the audience was comprised of 20 pharmacy students from these schools as well as nurse-practitioners […]
